Skip NavigationSkip to Content
Return Return to Search Results

Recent successes in therapeutics for Ebola virus disease: no time for complacency

  1. Author:
    Iversen, Patrick L.
    Kane, Christopher D.
    Zeng, Xiankun
    Panchal, Rekha G.
    Warren, Travis K.
    Radoshitzky, Sheli R.
    Kuhn, Jens H.
    Mudhasani, Rajini R.
    Cooper, Christopher L.
    Shurtleff, Amy C.
    Nasar, Farooq
    Sunay, Melek M. E.
    Duplantier, Allen J.
    Eaton, Brett P.
    Zumbrun, Elizabeth E.
    Bixler, Sandra L.
    Martin, Shannon
    Meinig, J. Matthew
    Chiang, Chih-Yuan
    Sanchez-Lockhart, Mariano
    Palacios, Gustavo F.
    Kugelman, Jeffrey R.
    Martins, Karen A.
    Pitt, Margaret L.
    Crozier,Ian
    Saunders, David L.

  2. Author Address

    US Army, Med Res Inst Infect Dis, Frederick, MD 21702 USA.NIAID, Integrated Res Facil Ft Detrick, Div Clin Res, NIH, Frederick, MD USA.Frederick Natl Lab Canc Res, Integrated Res Facil Ft Detrick, Clin Monitoring Res Program Directorate, Frederick, MD USA.
    1. Year: 2020
    2. Date: SEP
    3. Epub Date: 2020 06 18
  2. Journal: The Lancet. Infectious diseases
  3. ELSEVIER SCI LTD,
    1. 20
    2. 9
    3. Pages: E231-E237
  5. Type of Article: Review
  6. ISSN: 1473-3099
  1. Abstract:

    The PALM trial in the Democratic Republic of the Congo identified a statistically significant survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute Ebola virus disease; however, substantial gaps remain in improving the outcomes of acute Ebola virus disease and for the survivors. Ongoing efforts are needed to develop more effective strategies, particularly for individuals with severe disease, for prevention and treatment of viral persistence in immune-privileged sites, for optimisation of post-exposure prophylaxis, and to increase therapeutic breadth. As antibody-based approaches are identified and advanced, promising small-molecule antivirals currently in clinical stage development should continue to be evaluated for filovirus diseases, with consideration of their added value in combination approaches with bundled supportive care, their penetration in tissues of interest, the absence of interaction with glycoprotein-based vaccines, and filoviral breadth.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/S1473-3099(20)30282-6
  3. PMID: 32563280
  4. PMCID: PMC7302789
  5. View record in Web of Science®
  6. WOS: 000566754000007

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel